News
GOVXW
--
0.00%
--
GeoVax Announces Upcoming Presentations at Scientific Conferences
ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented duri...
GlobeNewswire · 05/04 13:00
BRIEF-GeoVax Reports 2022 First Quarter Financial Results
reuters.com · 04/27 20:50
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infec...
GlobeNewswire · 04/27 20:00
BRIEF-GeoVax Reports Issuance Of Malaria Vaccine Patent
reuters.com · 04/26 13:07
GeoVax Announces Issuance of Malaria Vaccine Patent
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human...
GlobeNewswire · 04/26 13:00
GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update
Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectio...
GlobeNewswire · 04/19 13:00
CORRECTION - Aura FAT Projects Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
Singapore, April 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire--In a release issued under the same headline on Monday, April 18th at 1:55 ET by GeoVax, Inc., please note that the release was distributed under the incorrect source and should have been sourc...
GlobeNewswire · 04/18 21:52
GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress
Company’s COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100% Protection in Lethal Animal Challenge Model Atlanta, GA, Apr...
GlobeNewswire · 04/12 13:00
GeoVax Announces Issuance of Cancer Vaccine Patent
IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate Atlanta, GA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious ...
GlobeNewswire · 03/22 13:00
GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022
Presentation to Focus on GEO-CM02 Being Developed as aUniversal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, March 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in dev...
GlobeNewswire · 03/21 13:00
GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference
Chairman & CEO David Dodd to Present Corporate UpdateCSO Mark Newman, PhD to Participate in Fireside Chatwith Maxim Analyst Jason McCarthy, PhD ATLANTA, GA , March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotech...
GlobeNewswire · 03/16 13:00
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
Comparative Trial Against Pfizer/BioNTech Vaccine Among Immunocompromised Patients Booster to Pfizer/BioNTech or Moderna Vaccines Among Healthy Patients ATLANTA, GA, March 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a ...
GlobeNewswire · 03/14 13:00
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2
GeoVax, Inc. GeoVax and City of Hope The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers LOS ANGELES and ATLANTA, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...
GlobeNewswire · 03/10 14:00
GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update
Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious dise...
GlobeNewswire · 03/09 21:00
GeoVax Announces Key Staff Appointments
Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer ATLANTA, GA, March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company speci...
GlobeNewswire · 03/07 14:00
GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update
Conference call to be held Wednesday, March 9, at 4:30 p.m. Eastern Time Atlanta, GA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious...
GlobeNewswire · 02/23 14:00
GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100
Atlanta, GA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chairman & CEO, David Dodd...
GlobeNewswire · 02/22 18:00
GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference
Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will p...
GlobeNewswire · 02/08 14:00
BRIEF-Geovax Announces Closing Of $10 Million Private Placement
reuters.com · 01/20 14:13
GeoVax Announces Closing of $10 Million Private Placement
Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced priva...
GlobeNewswire · 01/20 14:00
Webull provides a variety of real-time GOVXW stock news. You can receive the latest news about Geovax Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About GOVXW
GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a vector vaccine platform (Modified Vaccinia Ankara-Virus Like Particle or GV-MVA-VLP). It is focused on developing a vaccine for prevention of coronavirus (COVID-19) infection. The GV-MVA-VLP platform provides design and test vaccine to candidates, which differ through the inclusion of multiple SARS-CoV-2 proteins that are presented to the immune system as virus-like particles (VLPs). The Company's development programs are focused on preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa fever), Zika virus and malaria; preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV); as well as immunotherapies for solid tumor cancers. The Company is developing vaccines and immunotherapies for prevention or treatment of infectious diseases and cancer.